160 related articles for article (PubMed ID: 31666643)
21. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
Moreno Obregón F; Miramontes-González JP; Romo Guajardo-Fajardo C; Nieto-Sánchez Á; López-Suárez JM; Martín-Vallejo J; Arco-Prados Y; Dolores García de Lucas M; León-Jiménez D
Diabetes Res Clin Pract; 2019 Dec; 158():107916. PubMed ID: 31682882
[TBL] [Abstract][Full Text] [Related]
22. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
[TBL] [Abstract][Full Text] [Related]
23. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
[TBL] [Abstract][Full Text] [Related]
25. High-fat-diet induces airway hyperresponsiveness partly through activating CD38 signaling pathway.
Chong L; Zhang W; Yu G; Zhang H; Zhu L; Li H; Shao Y; Li C
Int Immunopharmacol; 2018 Mar; 56():197-204. PubMed ID: 29414651
[TBL] [Abstract][Full Text] [Related]
26. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
27. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
28. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
[TBL] [Abstract][Full Text] [Related]
29. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
Tuttle KR; Lakshmanan MC; Rayner B; Zimmermann AG; Woodward B; Botros FT
Diabetes Obes Metab; 2019 Jun; 21(6):1493-1497. PubMed ID: 30762290
[TBL] [Abstract][Full Text] [Related]
30. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice.
Sun X; Han F; Lu Q; Li X; Ren D; Zhang J; Han Y; Xiang YK; Li J
Diabetes; 2020 Jun; 69(6):1292-1305. PubMed ID: 32234722
[TBL] [Abstract][Full Text] [Related]
31. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
Benetti E; Mastrocola R; Vitarelli G; Cutrin JC; Nigro D; Chiazza F; Mayoux E; Collino M; Fantozzi R
J Pharmacol Exp Ther; 2016 Oct; 359(1):45-53. PubMed ID: 27440421
[TBL] [Abstract][Full Text] [Related]
33. Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission.
Mei X; Li Y; Wu J; Liao L; Lu D; Qiu P; Yang HL; Tang MW; Liang XY; Liu D
Biochem Biophys Res Commun; 2024 Jul; 716():150002. PubMed ID: 38697011
[TBL] [Abstract][Full Text] [Related]
34. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β.
Zhou M; Chen S; Peng P; Gu Z; Yu J; Zhao G; Deng Y
Biochem Biophys Res Commun; 2019 Mar; 511(1):154-160. PubMed ID: 30773255
[TBL] [Abstract][Full Text] [Related]
35. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
[TBL] [Abstract][Full Text] [Related]
36. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
37. Dulaglutide: A Review in Type 2 Diabetes.
Scott LJ
Drugs; 2020 Feb; 80(2):197-208. PubMed ID: 32002850
[TBL] [Abstract][Full Text] [Related]
38. Lipopolysaccharide Exposure Alleviates Asthma in Mice by Regulating Th1/Th2 and Treg/Th17 Balance.
Ding F; Fu Z; Liu B
Med Sci Monit; 2018 May; 24():3220-3229. PubMed ID: 29768397
[TBL] [Abstract][Full Text] [Related]
39. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type Ⅱ collagen and aggrecan in human SW1353 chondrocytes.
Li H; Chen J; Li B; Fang X
Chem Biol Interact; 2020 May; 322():108968. PubMed ID: 32004530
[TBL] [Abstract][Full Text] [Related]
40. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
de la Peña A; Cui X; Geiser J; Loghin C
Clin Pharmacokinet; 2017 Nov; 56(11):1415-1427. PubMed ID: 28357715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
